Beneficial effect of polaprezinc on cardiac function post-myocardial infarction

Abstract

Background:Polaprezinc is clinically used for the treatment of gastric ulcers. It induces the mobilization of mesenchymal stem cells and the mRNA expression of insulin-like growth factor-1 in vascular endothelial cells in order to protect injured gastric tissue or skin.Methods:The current study population included 50 patients with primary acute myocardial infarction (AMI). After percutaneous coronary intervention, the subjects were randomly divided into 2 groups, namely, the nonpolaprezinc and polaprezinc groups. Peripheral blood and urinary samples were collected in a specific time to analyze zinc concentration, cardiac enzymes, and the levels of the inflammation marker interleukin-6. To evaluate the cardiac function, echocardiography was performed upon admission to the hospital and at 9 months post-AMI.Results:The urine and blood zinc levels of the polaprezinc group were higher compared with those of the non-polaprezinc group at 8 days after percutaneous coronary intervention. The mean interleukin-6/maximal creatine phosphokinase level was significantly reduced in the polaprezinc group (0.024 [0.003–0.066] vs. 0.076 [0.015–0.212], respectively; P = .045). In addition, echocardiography revealed that the ejection fraction of the nonpolaprezinc group was not significantly increased between day 3 and 9 months post-AMI (53 [49–60.8] vs. 59.5 [52–69.3], respectively; P = .015). However, a significant increase was detected in the ejection fraction of the polaprezinc group at the 2 time points (54 [51–57] vs. 62 [55–71], respectively; P < .01).Conclusions:The results of the present study suggest that polaprezinc has an anti-inflammatory effect and improves cardiac function after AMI.

Trypanosoma cruzi iron superoxide dismutases: insights from phylogenetics to chemotherapeutic target assessment

“…Polaprezinc is a chelated form of zinc and L -carnosine that shows therapeutic activity for the treatment of pressure ulcers and other intestinal lesions [ 61 , 62 ], is used in cancer chemotherapy [ 63 , 64 ], presents therapeutic effects on cardiac function [ 65 ] and has a protective effect against respiratory diseases [ 66 ].…”

Oral management with polaprezinc solution reduces adverse events in haematopoietic stem cell transplantation patients

“…It has been reported that polaprezinc is not absorbed by normal epithelium, but it adheres to and infiltrates ulcer regions, inducing the activation of mesenchymal stem cells and the production of insulinlike growth factor-1 in vascular endothelial cells, and has wound healing-promoting effects and antiulcer actions to protect damaged gastric tissue and skin 21,22 . Regarding its antioxidant actions, it has been reported that polaprezinc removes free radicals in inflammatory regions; moreover, antioxidant markers, such as superoxide dismutase-1, superoxide dismutase-2, heme oxygenase-1, peroxiredoxin-1, and peroxiredoxin-V, have been reported to be increased in the rat model of polaprezinc treatment 23 .…”

Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis

“…1), 5 studies were excluded for the following reasons: unavailable data, inappropriate study design, and unrelated outcomes. At the end of the selection process, 14 studies [5,22,33,[48][49][50][51][52][53][54][55][56][57][58] meeting the inclusion criteria were eventually selected for systematic review and meta-analysis. The PRISMA checklist is presented as a Supplementary File.…”

“…Table 2 (Ref. [5,22,33,[48][49][50][51][52][53][54][55][56][57][58]) and Supplementary Table 1 list the basic characteristics of the studies that were included. These studies were published between 2011 and 2022.…”

“…Diabetes mellitus was found in 29% (4 out of 14) of the studies [22,33,52,57]. Two of the remaining four studies were on cancer [5,55], while the other two were on cardiovascular diseases [54,58]. Both genders were included in the majority of the studies.…”